Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Septerna, Inc.NASDAQ: SEPN

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables dips below year-ago levels

Q3 FY2026 accounts receivables of $6.72M (cash outflow) fell 20.8% year over year, behind the +21.4% change in trailing-twelve-month accounts receivables. Sequentially, it rose 410.2% from the prior quarter.

Context

  • Accounts receivables amounted to 22.2% of revenue in FY2025, up 20.3 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.8% toward the trailing-twelve-month pace of +21.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$6.72M+410.2% QoQ
Last fiscal yearDec 2025
-$10.19M+50825.0% YoY
LTMSep 2026
-$10.24M+21.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.8%——
1 year+50825.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(10.19M) USD
Year-over-year change
-50825.0%

Accounts Receivables vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 accounts receivables of $10.24M is the 3rd largest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of +21.4% is the highest of 2, against a peer median of -100.0%.
  • Accounts receivables amounts to 10.6% of revenue for SEPN, versus a peer median of 50.0%.
SEPN Competitors Peer median
Accounts Receivables for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$100.3M ———
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20M ——100.0%
SEPNSepterna, Inc.LTM Sep 2026$10.24M +21.4%—10.6%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 ———
KLRAKailera Therapeutics, Inc.FY2025$0 ———
VTVTvTv Therapeutics Inc.LTM Mar 2026$0 -100.0%—0.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$0 ———
Peer median (excluding SEPN) $0-100.0%—50.0%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.68M)4.18M(71.8M)(48.88M)
Depreciation & Amortization577K848K1.4M1.6M
Deferred Income Tax0491K(491K)0
Stock-Based Compensation1.52M1.62M3.15M8.48M
Change in Working Capital1.75M926K248K162.78M
Accounts Receivables0(151K)(20K)(10.19M)
Inventory0000
Accounts Payables1.73M(653K)723K6.6M
Other Working Capital20K1.73M(455K)166.36M
Other Non-Cash Items530K(46.79M)18K(13.79M)
Operating Cash Flow(23.3M)(38.72M)(67.47M)110.19M
Capital Expenditures(1.29M)(2.88M)(2.1M)(518K)
Acquisitions (Net)00012.5M
Purchases of Investments00(213.39M)(450.95M)
Sales of Investments0032.27M209.62M
Other Investing Activities025M22.63M0
Investing Cash Flow(1.29M)22.12M(160.6M)(229.35M)
Debt Repayment0000
Common Stock Issued82K0302.79M1.69M
Common Stock Repurchased0(1K)(1K)(1K)
Dividends Paid0000
Other Financing Activities0052K0
Financing Cash Flow30.05M74.52M377.78M1.69M
Effect of Forex Changes0000
Net Change in Cash5.46M57.92M149.71M(117.47M)
Free Cash Flow(24.59M)(41.6M)(69.57M)109.67M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.